CoChat
Sign Up
Cited by 98

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer

Hudson, R S, Yi, M, Esposito, D, Glynn, S A, Starks, A M, Yang, Y, Schetter, A J, Watkins, S K, Hurwitz, A A, Dorsey, T H, Stephens, R M, Croce, C M, Ambs, S·2013·Oncogene
DOI 10.1038/onc.2012.424PMC PMC3530025
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2012.424

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 32

  1. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524–15529. · DOI · Paper page
  2. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828–833. · DOI
  3. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635–647. · DOI
  4. Esquela-Kerscher A, Slack FJ . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–269. · DOI · Paper page
  5. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–152. · DOI
  6. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 3–50. · DOI
  7. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695–1699. · DOI
  8. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165–7169. · DOI · Paper page
  9. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM et al. Identification of the miR-106b∼25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010; 3: ra29. · DOI · Paper page
  10. Catto JW, Alcaraz A, Bjartell AS, De Vere WR, Evans CP, Fussel S et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011; 59: 671–681. · DOI
  11. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008; 68: 6162–6170. · DOI
  12. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010; 8: 529–538. · DOI
  13. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2011; 31: 978–991. · DOI
  14. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103: 9136–9141. · DOI
  15. Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090–1098. · DOI
  16. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de MI et al. E2F1-Regulated MicroRNAs Impair TGFbeta-Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell 2008; 13: 272–286. · DOI
  17. Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009; 136: 1689–1700. · DOI
  18. Li B, Shi XB, Nori D, Chao CK, Chen AM, Valicenti R et al. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 2011; 71: 567–574. · DOI
  19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22. · DOI
  20. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439–3443. · DOI
  21. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010; 3: 8. · DOI
  22. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene 2011; 30: 806–821. · DOI
  23. Yu J, Wang F, Yang GH, Wang FL, Ma YN, Du ZW et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun 2006; 349: 59–68. · DOI
  24. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012; 31: 4460–4471. · DOI
  25. Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T et al. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS ONE 2011; 6: e16138. · DOI
  26. Li Y, Tan W, Neo TW, Aung MO, Wasser S, Lim SG et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 2009; 100: 1234–1242. · DOI
  27. Gocek E, Wang X, Liu X, Liu CG, Studzinski GP . MicroRNA-32 Upregulation by 1,25-Dihydroxyvitamin D3 in Human Myeloid Leukemia Cells Leads to Bim Targeting and Inhibition of AraC-Induced Apoptosis. Cancer Res 2011; 71: 6230–6239. · DOI
  28. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009; 46: 497–510. · DOI
  29. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan A-C et al. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012; 31: 5162–5171. · DOI
  30. Petrocca F, Vecchione A, Croce CM . Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008; 68: 8191–8194. · DOI
  31. Reginato MJ, Mills KR, Paulus JK, Lynch DK, Sgroi DC, Debnath J et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003; 5: 733–740. · DOI
  32. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008; 68: 1152–1164. · DOI

Cited by

Sorted by citations

See all 98

Metadata

Authors
Hudson, R. S., Yi, M., Esposito, D., Glynn, S. A., Starks, A. M., Yang, Y., Schetter, A. J., Watkins, S. K., Hurwitz, A. A., Dorsey, T. H., Stephens, R. M., Croce, C. M., & Ambs, S.
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2012-09-17
Volume
32
Issue
35
Pages
4139-4147
ISSN
  • 0950-9232
  • 1476-5594
DOI
10.1038/onc.2012.424
PMC
PMC3530025
Cited by
98
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review